OpenEvidence’s $12 billion valuation reflects investor confidence in its bottom-up, doctor-first model. It has driven rapid adoption, with more than 757,000 clinicians using the startup’s free AI medical search tool regularly. That scale is paired with targeted pharmaceutical advertising that’s already pushed the company past a $100 million revenue run rate.
A group of healthcare researchers and health system leaders recently proposed a new framework to evaluate evidence for digital health products. The framework seeks to provide hospitals, payers and trade organizations with a clear set of steps they can use to determine whether or not a digital health product is evidence-based and therefore suitable for their company to adopt.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
In a lawsuit filed three years ago, Aetna alleged that Mednax had overbilled for medical procedures and services. Now, the insurer is accusing the medical group of destroying evidence pertaining to the suit and has asked a federal court to sanction Mednax.